Research programme: alprazolam transdermal gel - Antares

Drug Profile

Research programme: alprazolam transdermal gel - Antares

Alternative Names: AP-1002; AP-1022

Latest Information Update: 06 Jul 2010

Price : $50

At a glance

  • Originator Antares Pharma
  • Class Anxiolytics; Benzodiazepines; Small molecules
  • Mechanism of Action GABA B receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anxiety disorders

Most Recent Events

  • 23 Mar 2007 Preclinical development is ongoing
  • 30 Jun 2005 Preclinical trials in Anxiety disorders in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top